Diraman Emine, Demircan Gunnur, Demircan Sabri, Yazici Mustafa, Durna Kenan, Ural Firat, Eren Zafer
Department of Biology, Faculty of Science, Ondokuz Mayis University, Samsun, Turkey.
Exp Clin Cardiol. 2008 Summer;13(2):79-84.
To investigate the effect of glucose-insulin-potassium (GIK) infusion on erythrocyte antioxidant enzyme activity levels during therapy and post-therapy in patients with dilated cardiomyopathy (DCM).
Forty-one patients with DCM were enrolled in the present study. GIK solution (50 U of insulin in 500 mL of 30% glucose, plus 60 mmol/L KCl), in addition to the standard treatment, was administered by 24 h infusion in 28 patients (GIK group). In the remaining 13 patients (control group), 0.9% NaCl solution was administered. Venous blood samples from all patients were collected at baseline, during therapy (2 h, 8 h, 12 h and 24 h after baseline) and after therapy (48 h after baseline). The activity levels of superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSHP) were measured.
In the GIK group, SOD values showed a significant increase at 24 h and 48 h compared with baseline and 2 h values (P<0.05). An increasing trend in CAT activity was observed during and after GIK infusion compared with baseline (0 h) values. However, these differences were not statistically significant (P>0.05). With regard to GSHP activity, no significant change was found in the GIK group during follow-up (P>0.05). In the control group, SOD, CAT and GSHP activity levels measured during and after therapy were found to be similar to those measured at baseline (P>0.05).
Administration of GIK solution, in addition to standard therapy, in patients with DCM may improve the metabolic scope of the disease by reducing myocardial oxidative stress.
探讨葡萄糖-胰岛素-钾(GIK)输注对扩张型心肌病(DCM)患者治疗期间及治疗后红细胞抗氧化酶活性水平的影响。
本研究纳入41例DCM患者。28例患者(GIK组)在标准治疗基础上,通过24小时输注给予GIK溶液(500 mL 30%葡萄糖中含50 U胰岛素,加60 mmol/L氯化钾)。其余13例患者(对照组)给予0.9%氯化钠溶液。在基线、治疗期间(基线后2小时、8小时、12小时和24小时)及治疗后(基线后48小时)采集所有患者的静脉血样本。检测超氧化物歧化酶(SOD)、过氧化氢酶(CAT)和谷胱甘肽过氧化物酶(GSHP)的活性水平。
在GIK组中,与基线和2小时时的值相比,SOD值在24小时和48小时时显著升高(P<0.05)。与基线(0小时)值相比,在GIK输注期间及之后观察到CAT活性有增加趋势。然而,这些差异无统计学意义(P>0.05)。关于GSHP活性,GIK组在随访期间未发现显著变化(P>0.05)。在对照组中,治疗期间及治疗后测得的SOD、CAT和GSHP活性水平与基线时测得的水平相似(P>0.05)。
DCM患者在标准治疗基础上给予GIK溶液,可能通过降低心肌氧化应激来改善疾病的代谢范围。